New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.
Beyond the Ordinary Beyond the Obvious
Beyond the Ordinary Beyond the Obvious
New partnerships aim to expand Teva’s biosimilar portfolio and enhance access to high-cost biologics across key markets.
